TICK-BORNE DISEASE QUICK REFERENCE GUIDE FOR HEALTH CARE PROVIDERS

Disease	Incubation Period	Presentation	Laboratory Investigation	Initial Treatment
Anaplasmosis	5 to 21 days	 Acute onset of fever, chills, headache, arthralgia, nausea and vomiting often in association with leukopenia, thrombocytopenia and/or elevated liver enzymes. Severe manifestations are rare, though more common in older patients (> 60 years of age) and those with co-morbidities. 	 Serological evidence of a 4-fold change in specific IgG antibody titre in paired serum samples (2 - 4 weeks apart), OR Detection of DNA in a clinical specimen by specific PCR. 	Doxycycline 100mg PO BID for 2 weeks, unless contraindicated.
Babesiosis	1 to 6 weeks (may be up to 6 months following transfusion with infected blood products)	 Can be life threatening, particularly in older adults (> 50 years of age) and those with co-morbidities. Gradual onset of malaise and fatigue accompanied by intermittent fever. Additional symptoms may include: chills, drenching sweats, anorexia, headache, myalgia, nausea, non-productive cough, arthralgia and generalized weakness. Severe manifestations can include: acute respiratory distress syndrome, disseminated intravascular coagulation, hemodynamic instability, congestive heart failure, renal failure, hepatic compromise, myocardial infarction, severe hemolysis, splenic rupture and death. 	 Detection of parasites in blood smear by microscopy, OR Detection of DNA in whole blood specimen by specific PCR. Serological evidence is supportive if specific IgG antibody titre of ≥ 1:256. 4-fold rise in specific IgG antibody titre between acute and convalescent sera confirms recent infection. Titres ≥ 1:1024 suggest recent or active infections, those ≤ 1:64 suggest previous infection. 	 Mild to moderate disease: combination therapy with azithromycin and atovaquone OR clindamycin and quinine for 7 - 10 days. Severe disease: combination therapy with clindamycin and quinine. Duration depends on clinical course. Consultation with infectious diseases is strongly recommended for suspected clinical cases.
Lyme disease (LD)	Symptoms, incubation period, laboratory diagnostics and treatments vary depending on the stage			
	Post-exposure prophylaxis – within 72 hours of tick removal	 Asymptomatic adults/children when the following criteria are met: 1) Tick reliably identified as an adult or nymph blacklegged tick (<i>Ixodes scapularis</i>), and 2) Tick was attached for ≥ 36 hours or tick is engorged, and 3) Tick acquired from a high risk area* (anywhere in southern Manitoba (south of the 53rd parallel) with suitable habitat), and 4) Doxycycline is not contraindicated. 	Diagnostic testing of asymptomatic patients following a tick bite is not recommended.	 > 12 years: Doxycycline 200 mg PO x 1; 8 - 12 years: Doxycycline 4 mg/kg (maximum 200 mg) PO x 1; Unless contraindicated.
	Early localized LD – 3 to 30 days	• Erythema migrans (EM) or non-specific flu-like symptoms (i.e. fatigue, fever, headache, mildly stiff neck, arthralgia or myalgia and lymphadenopathy).	 Acute & convalescent sera are recommended (3 - 4 weeks apart). Serological tests may be negative within first 	 Doxycycline 100mg PO BID for 2 - 3 weeks, unless contraindicated.
	Early disseminated LD – days to months	 Multiple EM, CNS (lymphocytic meningitis, and rarely, encephalomyelitis) & PNS (radiculopathy, cranial neuropathy, and mononeuropathy multiplex) or cardiac (intermittent atrioventricular heart block, myoepicarditis) symptoms. 	6 weeks of infection. Individuals treated early in the infection may not seroconvert and never meet Western Blot positivity criteria.	 Same as early localized LD oral regimen, OR Ceftriaxone 2g IV for 2 - 3 weeks for those with neuro or cardiac symptoms.
	Late LD – months to years	Intermittent recurring arthritis (usually monoarticular) or neurological symptoms. Ited based on clinical suspicion of disease. Depending on symptoms and the second of the second	A single sera sample is sufficient.	 Doxcycline 100mg PO BID for 4 weeks, OR Ceftriaxone 2g IV for 2 - 4 weeks.

- Treatment should be initiated based on clinical suspicion of disease. Depending on symptoms and timing of diagnosis, some cases may require a longer or repeat course of treatment. Where above treatments are contraindicated consult the communicable disease management protocols available at www.gov.mb.ca/health/publichealth/cdc/tickborne/index.html for additional options.
- Co-infection should be considered if there is a more severe clinical presentation, if symptoms persist or there is a poor response to recommended therapies. Consultation with ID is recommended.
- High risk areas in Canada, outside of Manitoba, can be found at: https://phrsgeomatics.maps.arcgis.com/apps/dashboards/95179b3e96fa4214a408e3611b0dce6b
- Additional resources include:
 - o https://www.cps.ca/en/documents/position/lyme-disease-children
 - o https://www.idsociety.org/practice-guideline/lyme-disease/